Psychopharmacology and psychotropic medicines in children and adolescents — OSCE communication station

Station objectives

1. Conduct a shared decision-making conversation with an adolescent and parent about starting an SSRI, including the indication, the combination with therapy, and the expected timeline. [1]
2. Counsel honestly and accurately on the FDA black-box suicidality warning, common side effects, and the review schedule. [8]
3. Recognise SSRI activation or suicidality at early review and respond with a safe plan. [9]

Candidate brief

You are the paediatric registrar in clinic. You have 8 minutes for Station A (a shared decision-making conversation with a 15-year-old with moderate major depression and her mother about whether to start fluoxetine) and 6 minutes for Station B (a scheduled phone review two weeks later in which she reports new agitation, restlessness and a fleeting intrusive thought of self-harm). Examiners score rapport and consent quality, accurate counselling on the suicidality warning and timeline, and the safe response to deterioration. [1] [8]

Station A — Shared decision-making: starting fluoxetine

Setup: A 15-year-old with moderate major depression (PHQ-A moderate-severe), four weeks of low mood, anhedonia, sleep and appetite disturbance, declining school attendance, fleeting passive suicidal thoughts but no plan or intent. No history of mania or psychosis. Her mother asks whether she needs tablets and what the risks are. [1]

Expected actions:

• Establish rapport with the adolescent first and separately, respecting her autonomy and confidentiality. [1]
• Summarise the diagnosis, severity and functional impact, and confirm that psychoeducation, CBT and fluoxetine together are the evidence-based plan, citing TADS that combination therapy is best and lowers suicidality compared with fluoxetine alone. [1] [2]
• Explain that fluoxetine is first-line with the strongest paediatric evidence; name that paroxetine is not first-line and why (Restoring Study 329). [10]
• Counsel honestly on the FDA black-box suicidality warning: what it means, why it does not mean avoiding treatment, and what to watch for in the first weeks. [8] [9]
• State the expected timeline (4 to 6 weeks to benefit), common side effects (gastrointestinal upset, sleep change, activation), and the review schedule at 1, 2 and 4 weeks and at every dose change. [1]
• Give a written safety plan, remove access to means, and provide an open-access pathway. Confirm the exact starting dose against the local paediatric formulary. [1]

Station B — Deterioration at two weeks: SSRI activation

Setup: Two weeks into fluoxetine, the adolescent phones the clinic reporting she feels "wired and worse," with inner restlessness, insomnia, and a fleeting intrusive thought of self-harm that scared her. [9]

Expected actions:

• Recognise the SSRI activation and suicidality signal in the early treatment window; do not dismiss it as "just the illness." [8]
• Conduct a structured risk assessment: current suicidal intent, plan, means access, protective factors, and current symptoms. [9]
• Decide on the immediate response: stop or reduce the SSRI, institute or update the safety plan, remove access to means, and arrange urgent mental-health review and a face-to-face assessment the same day. [8]
• Communicate clearly and calmly with the adolescent and her mother, and document the decision and follow-up. [9]

Marking anchors

Clear pass: establishes rapport with the adolescent; explains the diagnosis and the combination-therapy rationale citing TADS; counsels honestly on the black-box warning without alarming or minimising; states the 4 to 6 week timeline, common side effects, and the 1-, 2-, 4-week review schedule; gives a safety plan and open access; recognises activation and suicidality at two weeks; conducts a structured risk assessment; stops or reduces the SSRI; arranges urgent review and same-day assessment; documents clearly. [1] [8] [9] Borderline: good rapport but vague on the timeline or the review schedule, or counsels the warning in a way that either over-alarms or minimises it, or recognises deterioration but the safety response is incomplete. Fail: prescribes without explaining the warning; dismisses early agitation as expected without a risk assessment; fails to arrange urgent review; or does not give a safety plan. [8] [9]

Debrief pearls

• TADS: fluoxetine plus CBT is safer and better than fluoxetine alone — combination lowers suicidality. [1] [2]
• The black-box warning demands monitoring, not avoidance: untreated depression carries its own substantial suicide risk. [8] [9]
• Early agitation, restlessness or new intrusive thoughts on an SSRI are the activation signal — act, do not reassure and wait. [9]
• Confirm every starting dose against the local paediatric formulary (BNF for Children / AMH Children's Dose). [1]